News
-
Insmed has announced that it will move ahead with a Phase 3 trial of Arikayce inhaled liposomal amikacin for the treatment of nontuberculous mycobacteria (NTM) lung infections, with results expected in 2017. According to the… Read more . . .
-
Alexza Pharmaceuticals has announced that it will develop Staccato versions of ropinirole, a dopamine agonist, for the treatment of restless leg system (AZ-008) and for the treatment of hypomobility during OFF episodes in Parkinson’s disease… Read more . . .
-
The FDA has announced the approval of Boehringer Ingelheim’s Striverdi Respimat olodaterol SMI for the treatment of COPD. The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) recommended approval of Striverdi Respimat in January 2013. The soft… Read more . . .
-
Mystic Pharmaceuticals has announced that the United States Patent and Trade Office issued a Notice of Allowance for the company’s patent application titled “Medical Devices For Dispensing Powders” (application #13/433,586). The technology is an extension… Read more . . .
-
AstraZeneca will pay $875 million initially, plus up to an additional $1.22 billion to acquire development and commercialization rights to Almirall’s entire respiratory drug business. Almirall’s respiratory products include the Eklira/Bretaris/Tudorza aclidinium DPI, an aclidinium/formoterol… Read more . . .
-
Malvern Instruments has announced the purchase of the Archimedes particle characterization system from Affinity Biosensors after having had an exclusive distribution agreement outside of North America and a co-marketing agreement in North America for the… Read more . . .
-
GlaxoSmithKline has announced that the FDA has approved its Flonase fluticasone propionate nasal spray for the treatment of allergic rhinitis for over-the-counter sale. The approval is for a 50 mcg spray, the same as the… Read more . . .
-
Canadian pharmaceutical company Milestone Pharmaceuticals, which is developing an intranasal short-acting calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia, has announced the appointment of Francis Plat as Chief Medical Officer. Dr. Plat commented,… Read more . . .
-
Lightlake Therapeutics has announced that it filed an investigational new drug application for its intranasal naloxone therapy for the reversal of opioid overdose. The company also said that it has received additional funding from the… Read more . . .
-
CD-adapco has announced that STAR-CCM+ v9.04, the latest release of its simulation software, includes new physics models useful for development and analysis of various types of OINDPs in addition to offering significantly faster operation. The… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.